Tirzepatide

Tirzepatide is a synthetic peptide investigated for coordinated activation of GIP and GLP-1 receptors and the resulting incretin and downstream metabolic signaling.

Agonizes both GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon regulation, gastric emptying, appetite, and energy-balance pathways.

Substantial controlled human evidence and FDA-approved drug products.

Level I, Established human evidence

Clinical evidence pertains to approved formulations manufactured under regulated pharmaceutical conditions and does not establish equivalence of unrelated research products.

Approved-product information describes gastrointestinal reactions, pancreatitis and gallbladder concerns, hypoglycemia in certain combinations, and a boxed warning concerning thyroid C-cell tumors observed in rats.

The active ingredient is used in FDA-approved prescription drugs; research material is not an approved drug product.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.